Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.

Chen WT, White CM, Phung OJ, Kluger J, Ashaye AO, Sobieraj DM, Makanji S, Tongbram V, Baker WL, Coleman CI.

Mayo Clin Proc. 2011 Jun;86(6):509-21. doi: 10.4065/mcp.2010.0755. Review.

2.

Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review.

Chen WT, White CM, Phung OJ, Kluger J, Ashaye A, Sobieraj D, Makanji S, Tongbram V, Baker WL, Coleman CI.

Int J Clin Pract. 2011 Jul;65(7):749-63. doi: 10.1111/j.1742-1241.2011.02694.x. Review.

PMID:
21676118
3.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

4.

Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation.

Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR.

Am J Med. 2012 Jun;125(6):603.e1-6. doi: 10.1016/j.amjmed.2011.09.030. Epub 2012 Apr 11.

5.

Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ; ORBIT-AF Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):461-9. doi: 10.1161/CIRCOUTCOMES.113.000127. Epub 2013 Jun 11.

6.

Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use.

Casciano JP, Singer DE, Kwong WJ, Fox ES, Martin BC.

Am J Cardiovasc Drugs. 2012 Oct 1;12(5):313-23. doi: 10.2165/11634150-000000000-00000.

PMID:
22920047
7.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
8.

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.

Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.

Am J Geriatr Pharmacother. 2009 Jun;7(3):159-66. doi: 10.1016/j.amjopharm.2009.06.002.

PMID:
19616184
9.

Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.

Hess CN, Broderick S, Piccini JP, Alexander KP, Newby LK, Shaw LK, Mahaffey KW, Alexander JH, Peterson ED, Granger CB, Lopes RD.

Am Heart J. 2012 Oct;164(4):607-15. doi: 10.1016/j.ahj.2012.07.004.

10.
11.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
12.

Can we predict stroke in atrial fibrillation?

Lip GY.

Clin Cardiol. 2012 Jan;35 Suppl 1:21-7. doi: 10.1002/clc.20969. Review.

13.

[Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].

Tomita F, Kohya T, Kitabatake A.

Nihon Rinsho. 2000 Jun;58(6):1326-34. Review. Japanese.

PMID:
10879060
14.

The impact of CHADS2 score on late stroke after the Cox maze procedure.

Pet M, Robertson JO, Bailey M, Guthrie TJ, Moon MR, Lawton JS, Rinne A, Damiano RJ Jr, Maniar HS.

J Thorac Cardiovasc Surg. 2013 Jul;146(1):85-9. doi: 10.1016/j.jtcvs.2012.03.087. Epub 2012 Jul 19.

15.

Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?

Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M.

Am J Med. 2010 May;123(5):446-53. doi: 10.1016/j.amjmed.2009.11.015.

PMID:
20399322
16.
17.

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee.

Can J Cardiol. 2011 Jan-Feb;27(1):74-90. doi: 10.1016/j.cjca.2010.11.007.

PMID:
21329865
18.

Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study.

Naganuma M, Shiga T, Sato K, Murasaki K, Hashiguchi M, Mochizuki M, Hagiwara N.

Thromb Res. 2012 Jul;130(1):21-6. doi: 10.1016/j.thromres.2011.11.005. Epub 2011 Dec 3.

PMID:
22137743
19.

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators.

Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

20.

The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation.

Ad N, Henry L, Schlauch K, Holmes SD, Hunt S.

Ann Thorac Surg. 2010 Oct;90(4):1257-62. doi: 10.1016/j.athoracsur.2010.05.010.

PMID:
20868824

Supplemental Content

Support Center